e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Systemic therapy of lung cancer and quality of life
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
ERCC1 and MDR1 expression and polymorphism frequency related to clinical outcome and chemotherapy response in a Brazilian sample of NSCLC patients
L. Zambon, A. P. Salles Perroud, M. Toledo Leme, E. Mello De Capitani, M. Wesley Perroud, Jr., A. Souza Barbeiro, B. Alonso Saad, J. Vassalo, A. Morcillo, D. Botelho Costa, H. Naemi Honma (Campinas, Brazil; Boston, United States Of America)
Source:
Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Session:
Systemic therapy of lung cancer and quality of life
Session type:
Thematic Poster Session
Number:
4498
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Zambon, A. P. Salles Perroud, M. Toledo Leme, E. Mello De Capitani, M. Wesley Perroud, Jr., A. Souza Barbeiro, B. Alonso Saad, J. Vassalo, A. Morcillo, D. Botelho Costa, H. Naemi Honma (Campinas, Brazil; Boston, United States Of America). ERCC1 and MDR1 expression and polymorphism frequency related to clinical outcome and chemotherapy response in a Brazilian sample of NSCLC patients. Eur Respir J 2013; 42: Suppl. 57, 4498
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
EGFR frequency and response to chemotherapy in a Brazilian NSCLC population
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
A functional polymorphism in
XRCC1
gene is associated with lung cancer risk in a Korean population
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
A polymorphism, which exists intronic lesion of SLC5A10, affects DRG2 expression and survival outcome of early-stage non-small cell lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Association of XPD and CDA polymorphisms with clinical outcome in non-small cell lung cancer in a Chinese population
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Tumor laterality influences the prognostic impact of Bcl-2 expression in curatively resected NSCLC patients
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Are Vitamin D receptor genetic polymorphisms associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer?
Source: International Congress 2016 – Molecular targets in pulmonary disease
Year: 2016
The association of cyclooxygenase 2 single-nucleotide polymorphisms with susceptibility to and severity of non-small cell lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
The significance of HSP90AA1, HSP90AB1 and HSP90B1 gene polymorphisms in a Turkish population with non-small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Loss of heterozygosity of PTEN in patients with non-small cell lung cancer treated and not treated with neoadjuvant chemotherapy
Source: Annual Congress 2013 –Genetics and genomics of lung disease
Year: 2013
The effects of polymorphisms identified in genome-wide association studies of never-smoking females on the prognosis of non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Characteristics and prognostic relevance of
p
53 gene mutations in Polish non small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005
Association of -93G®A polymorphism in the
hMLH1
gene with susceptibility to and prognosis of non-small cell lung cancer in Taiwan
Source: Eur Respir J 2006; 28: Suppl. 50, 151s
Year: 2006
RT-PCR expression of EML4-ALK oncogene in Bulgarian patients with non-small cell lung cancers
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Prevalence of mutations in Romanian patients with non-squamous lung carcinoma evaluated through next generation sequencing
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept